Information Provided By: 
Fly News Breaks for November 17, 2015
VRX
Nov 17, 2015 | 07:40 EDT
Morgan Stanley analyst David Risinger cut Valeant estimates and lowered his price target to $98 from $200 to account for the negative impact of Philidor and uncertainty in U.S. growth. Risinger believes Valeant is a "real" company selling "real" drugs despite Philidor and other controversies, but cannot ignore the investigation risks or quantify the costs at this time. The analyst continues to rate shares Equal Weight, despite low valuation, until visibility increases.
News For VRX From the Last 2 Days
There are no results for your query VRX
